Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma

被引:19
作者
Aroldi, Francesca [1 ]
Middleton, Mark R. [1 ]
机构
[1] Univ Oxford, Dept Oncol, Oxford OX 37LE, England
关键词
QUALITY-OF-LIFE; PHASE-III; OPEN-LABEL; DOUBLE-BLIND; STAGE IV; ADJUVANT PEMBROLIZUMAB; COMBINED NIVOLUMAB; SURVIVAL OUTCOMES; PLUS IPILIMUMAB; CHEMOTHERAPY;
D O I
10.1007/s40257-022-00681-4
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Increasing knowledge about the biology of melanoma and of immunology has led to the development and regulatory approval of the immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab, which are indicated for the treatment of melanoma irrespective of the B-Raf proto-oncogene mutation status of the tumour. Only a subset of patients will respond, but those who do can expect long-lasting, previously unheard-of responses. Long-term survival results for the registration trials, including CheckMate 067, Keynote-006, and Keynote-001, have recently been published. In particular, the combination of ipilimumab and nivolumab showed an impressive 5-year overall survival of just over 50%. However, toxicity remains a significant concern, with some of the side effects being life threatening and/or life changing. In this review, we discuss the safety and efficacy data of all the agents currently approved for the first-line treatment of advanced melanoma, identifying factors that influence the choice of a single agent rather than combination therapy. We highlight the potential biomarkers of response, effects of long-term toxicity, and options after progression.
引用
收藏
页码:331 / 338
页数:8
相关论文
共 64 条
[1]   Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma [J].
Alva, Ajjai ;
Daniels, Gregory A. ;
Wong, Michael K. K. ;
Kaufman, Howard L. ;
Morse, Michael A. ;
McDermott, David F. ;
Clark, Joseph I. ;
Agarwala, Sanjiv S. ;
Miletello, Gerald ;
Logan, Theodore F. ;
Hauke, Ralph J. ;
Curti, Brendan ;
Kirkwood, John M. ;
Gonzalez, Rene ;
Amin, Asim ;
Fishman, Mayer ;
Agarwal, Neeraj ;
Lowder, James N. ;
Hua, Hong ;
Aung, Sandra ;
Dutcher, Janice P. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (12) :1533-1544
[2]  
[Anonymous], 2021, J CLIN ONCOL, V39
[3]   INITIAL RESULTS OF A PHASE 1 TRIAL OF RP2, A FIRST IN CLASS, ENHANCED POTENCY, ANTI-CTLA-4 ANTIBODY EXPRESSING, ONCOLYTIC HSV AS SINGLE AGENT AND COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS [J].
Aroldi, Francesca ;
Sacco, Joseph ;
Harrington, Kevin ;
Olsson-Brown, Anna ;
Nanclares, Pablo ;
Menezes, Lavita ;
Bommareddy, Praveen ;
Thomas, Suzanne ;
Kaufman, Howard ;
Samakoglu, Selda ;
Coffin, Robert ;
Middleton, Mark .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 :A256-A257
[4]   Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial [J].
Ascierto, Paolo A. ;
Del Vecchio, Michele ;
Mandala, Mario ;
Gogas, Helen ;
Arance, Ana M. ;
Dalle, Stephane ;
Cowey, C. Lance ;
Schenker, Michael ;
Grob, Jean-Jacques ;
Chiarion-Sileni, Vanna ;
Marquez-Rodas, Ivan ;
Butler, Marcus O. ;
Maio, Michele ;
Middleton, Mark R. ;
de la Cruz-Merino, Luis ;
Arenberger, Petr ;
Atkinson, Victoria ;
Hill, Andrew ;
Fecher, Leslie A. ;
Millward, Michael ;
Khushalani, Nikhil, I ;
Queirolo, Paola ;
Lobo, Maurice ;
de Pril, Veerle ;
Loffredo, John ;
Larkin, James ;
Weber, Jeffrey .
LANCET ONCOLOGY, 2020, 21 (11) :1465-1477
[5]   Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial [J].
Ascierto, Paolo A. ;
Long, Georgina V. ;
Robert, Caroline ;
Brady, Benjamin ;
Dutriaux, Caroline ;
Di Giacomo, Anna Maria ;
Mortier, Laurent ;
Hassel, Jessica C. ;
Rutkowski, Piotr ;
McNeil, Catriona ;
Kalinka-Warzocha, Ewa ;
Savage, Kerry J. ;
Hernberg, Micaela M. ;
Lebbe, Celeste ;
Charles, Julie ;
Mihalcioiu, Catalin ;
Chiarion-Sileni, Vanna ;
Mauch, Cornelia ;
Cognetti, Francesco ;
Ny, Lars ;
Arance, Ana ;
Svane, Inge Marie ;
Schadendorf, Dirk ;
Gogas, Helen ;
Saci, Abdel ;
Jiang, Joel ;
Rizzo, Jasmine ;
Atkinson, Victoria .
JAMA ONCOLOGY, 2019, 5 (02) :187-194
[6]   Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma [J].
Asher, Nethanel ;
Ben-Betzalel, Guy ;
Lev-Ari, Shaked ;
Shapira-Frommer, Ronnie ;
Steinberg-Silman, Yael ;
Gochman, Neta ;
Schachter, Jacob ;
Meirson, Tomer ;
Markel, Gal .
CANCERS, 2020, 12 (08) :1-18
[7]  
Atkins MB, 2000, CANCER J SCI AM, V6, pS11
[8]   Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards [J].
Bottomley, Andrew ;
Pe, Madeline ;
Sloan, Jeff ;
Basch, Ethan ;
Bonnetain, Franck ;
Calvert, Melanie ;
Campbell, Alicyn ;
Cleeland, Charles ;
Cocks, Kim ;
Collette, Laurence ;
Dueck, Amylou C. ;
Devlin, Nancy ;
Flechtner, Hans-Henning ;
Gotay, Carolyn ;
Greimel, Eva ;
Griebsch, Ingolf ;
Groenvold, Mogens ;
Hamel, Jean-Francois ;
King, Madeleine ;
Kluetz, Paul G. ;
Koller, Michael ;
Malone, Daniel C. ;
Martinelli, Francesca ;
Mitchell, Sandra A. ;
Moinpour, Carol M. ;
Musoro, Jammbe ;
O'Connor, Daniel ;
Oliver, Kathy ;
Piault-Louis, Elisabeth ;
Piccart, Martine ;
Pimentel, Francisco L. ;
Quinten, Chantal ;
Reijneveld, Jaap C. ;
Schuermann, Christoph ;
Smith, Ashley Wilder ;
Soltys, Katherine M. ;
Taphoorn, Martin J. B. ;
Velikova, Galina ;
Coens, Corneel .
LANCET ONCOLOGY, 2016, 17 (11) :E510-E514
[9]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[10]   Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study [J].
Callahan, Margaret K. ;
Kluger, Harriet ;
Postow, Michael A. ;
Segal, Neil H. ;
Lesokhin, Alexander ;
Atkins, Michael B. ;
Kirkwood, John M. ;
Krishnan, Suba ;
Bhore, Rafia ;
Horak, Christine ;
Wolchok, Jedd D. ;
Sznol, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) :391-+